Evidence map›Paper›PMID 38450623›Full record

Trial reportCell transplantation

Human Umbilical Cord-Derived Mesenchymal Stem Cells in the Treatment of Multiple Sclerosis Patients: Phase I/II Dose-Finding Clinical Study.

Fatima Jamali, Mayis Aldughmi, Serin Atiani, Ali Al-Radaideh, Said Dahbour, Dana Alhattab, Hind Khwaireh, Sally Arafat, Joud Al Jaghbeer, Reem Rahmeh and 7 more

Open access · goldAbstract readClinical Trial, Phase IIClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cell transplantation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
8.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Mesenchymal stem cells for recurrent miscarriage.Journal of translational medicine · 2026
    Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 4 countries.

Fatima JamaliCell Therapy Center, The University of Jordan, Amman, Jordan.
Mayis AldughmiDepartment of Physical Therapy, School of Rehabilitation Sciences, The University of Jordan, Amman, Jordan.
Serin AtianiData Science Department, Princess Sumaya University for Technology, Amman, Jordan.
Ali Al-RadaidehDivision of Neurology, Department of Internal Medicine, Faculty of Medicine, Jordan University Hospital, The University of Jordan, Amman, Jordan.
Said DahbourDepartment of Medical Imaging, Faculty of Applied Medical Sciences, The Hashemite University, Zarqa, Jordan.
Dana AlhattabCell Therapy Center, The University of Jordan, Amman, Jordan.ORCID 0000-0002-0509-6182
Hind KhwairehCell Therapy Center, The University of Jordan, Amman, Jordan.
Sally ArafatCell Therapy Center, The University of Jordan, Amman, Jordan.
Joud Al JaghbeerDepartment of Physical Therapy, School of Rehabilitation Sciences, The University of Jordan, Amman, Jordan.
Reem RahmehCell Therapy Center, The University of Jordan, Amman, Jordan.
Kawthar Abu MoshrefCell Therapy Center, The University of Jordan, Amman, Jordan.
Hisham BawanehHematology Department, Jordan University Hospital, Amman, Jordan.
Mona R HassunehDepartment of Applied Biology, College of Sciences, University of Sharjah, Sharjah, United Arab Emirates.
Bayan HouraniCell Therapy Center, The University of Jordan, Amman, Jordan.
Osameh AbabnehDepartment of Ophthalmology, Jordan University Hospital, School of Medicine, The University of Jordan, Amman, Jordan.
Alia AlghwiriDepartment of Physical Therapy, School of Rehabilitation Sciences, The University of Jordan, Amman, Jordan.
Abdalla AwidiCell Therapy Center, The University of Jordan, Amman, Jordan.
University of Jordan · JOJordan Hospital · JOPrincess Sumaya University for Technology · JO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple sclerosis (MS) is a chronic neuro-inflammatory disease resulting in disabilities that negatively impact patients' life quality. While current treatment options do not reverse the course of the disease, treatment using mesenchymal stromal/stem cells (MSC) is promising. There has yet to be a consensus on the type and dose of MSC to be used in MS. This work aims to study the safety and efficacy of two treatment protocols of MSCs derived from the umbilical cord (UC-MSCs) and their secretome. The study included two groups of MS patients; Group A received two intrathecal doses of UC-MSCs, and Group B received a single dose. Both groups received UC-MSCs conditioned media 3 months post-treatment. Adverse events in the form of a clinical checklist and extensive laboratory tests were performed. Whole transcriptome analysis was performed on patients' cells at baseline and post-treatment. Results showed that all patients tolerated the cellular therapy without serious adverse events. The general disability scale improved significantly in both groups at 6 months post-treatment. Examining specific aspects of the disease revealed more parameters that improved in Group A compared to Group B patients, including a significant increase in the (CD3

Indexed as

Mesenchymal Stem CellsMicroRNAsMultiple SclerosisCell- and Tissue-Based TherapyHumansStem CellsMicroRNAsconditioned mediumdose findingmesenchymal stem cellsmultiple sclerosisumbilical cord

Identifiers

PMID38450623
PMCPMC10921855
OpenAlexW4392551581

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.